Every vaccine must be safe, effective and well-tested before it receives marketing authorization in the EU or Germany. The manufacturer must provide this proof in preclinical studies and clinical trials.
In Germany, a vaccine is only approved if it passes all three phases of the clinical trial program. These national and international quality standards apply - as they do to all other vaccine developments - to the approval of a Corona vaccine. Until a few years ago, stakeholders would have estimated up to 20 years to go through all stages. But new technologies, prior experience with vaccine projects against related viruses (e.g., MERS-CoV), and intensive collaboration with the responsible authorities have made it possible to develop a vaccine that meets quality requirements faster than ever before.
Five vaccines against the Corona virus have been approved in the European Union to date (as of March 2022). These are the vaccines from the pharmaceutical companies Biontech/Pfizer, Moderna, Astrazeneca, Johnson & Johnson and Novavax.
They are based on the recommendations of the European Medicines Agency (EMA). An overview of the current development status of the various vaccines can be found on the EMA website.
According to the World Health Organization (WHO), more than 100 potential vaccines are currently undergoing clinical trials worldwide. Here you can find the compilation of the WHO (eng.)
The vaccines from Biontech/Pfizer and Moderna are so-called mRNA vaccines.
The vaccines from Astrazeneca and Johnson & Johnson are so-called vector-based vaccines. The vaccine from Novavax is a protein vaccine.
Further information on the mode of action and safety of the vaccines: www.zusammengegencorona.de/infos-zum-impfen/informationen-fuer-buerger-innen and www.bundesregierung.de/breg-de/themen/coronavirus/coronavirus-impfung-faq-1788988
Vaccination centers and vaccination sites have at their disposal mRNA vaccines, vector vaccines and, since February 2022, the protein vaccine Nuvaxovid.
Please note that there is generally no choice of vaccine. The selection of the vaccine suitable for you will be made, if necessary on site, according to the applicable recommendations regarding age, vaccine combinations, pre-existing diseases and other parameters.
However, if you wish to receive the newly approved protein vaccine Nuvaxovid from the manufacturer Novavax, you can indicate this in the registration process for your vaccination appointment. Individuals who do not indicate nuvaxovid vaccine as a request on the registration form will receive a different vaccine.
Combinations of nuvaxovid and mRNA or vector vaccines are possible under certain circumstances. For more information, see "What information should be considered for vaccination with the Novavax vaccine?"
If you wish to receive the Nuvaxovid vaccine for a second or booster vaccination, you must specify this as part of the registration process.
Please be sure to note the following information about the vaccine Nuvaxovid from the manufacturer Novavax.
Since February 28, 2022, it has been possible to be vaccinated with the new vaccine Nuvaxovid from Novavax at the vaccination centers in Rhineland-Palatinate.
The STIKO recommends the vaccine for basic immunization of persons aged 18 years and older. Two vaccine doses are to be given at least 3 weeks apart. The use of Nuvaxovid during pregnancy and lactation is not recommended at this time.
If you decide to be vaccinated with the Nuvaxovid vaccine, you will receive the first and second vaccinations with this vaccine. A second vaccination with Nuvaxovid after an initial vaccination with another vaccine (mRNA or vector vaccine) is generally not intended. According to the currently recommended vaccination scheme of the STIKO, the second vaccination after an initial vaccination with the Johnson and Johnson vaccine is an exception see Table 1 In: Epidemiologisches Bulletin 7/2022 of the RKI.
Unvaccinated individuals with a history of SARS-CoV-2 infection may receive one dose of Nuvaxovid vaccine to complete the basic immunization series.
If there is a product-specific, medical contraindication to continuing the vaccination series after administration of the 1st vaccination with another COVID-19 vaccine, the basic immunization can be completed with Nuvaxovid. This requires the presentation of a general practitioner's certificate to the vaccination center clearly stating that nuvaxovid should be vaccinated. The indication of a disease diagnosis alone is not sufficient.
The STIKO recommends that ® persons 18 years of age and older who have been vaccinated with Nuvaxovid receive a booster vaccination with an mRNA vaccine at a minimum interval of 3 months from the completed basic immunization.
Currently, there is no approval for Nuvaxovid for booster vaccination. According to the STIKO, Nuvaxovid® can be offered as a booster vaccination in individual cases after medical clarification if there are contraindications to mRNA-COVID-19 vaccines. This also requires the presentation of a general practitioner's certificate to the vaccination center, which clearly states that Nuvaxovid should be vaccinated. The indication of a disease diagnosis alone is not sufficient.
It is of great importance for medical research that as many people as possible report on their vaccination and the tolerability of the respective vaccine. Please use the online form to indicate whether and from which side effects you were affected.